No data

N-Acetyl Semax Amidate

N-Acetyl-Met-Glu-His-Phe-Pro-Gly-Pro-NH2

Overview

N-Acetyl Semax Amidate (NASHA) is a modified version of Semax with an acetyl group added to the N-terminus and amidation at the C-terminus. These modifications significantly increase potency and duration of action compared to standard Semax making NASHA approximately 1000 times more potent by weight. It is considered by many in the nootropic research community to be the superior form of Semax offering the same cognitive and neuroprotective benefits at much lower doses with longer lasting effects.

Mechanism of Action

NASHA shares Semax's core mechanism — BDNF and NGF upregulation dopaminergic and serotonergic modulation and neuroprotection — but the chemical modifications dramatically alter its pharmacokinetics. The N-acetyl modification protects the peptide from aminopeptidase degradation while the C-terminal amidation protects from carboxypeptidase breakdown. Together these modifications extend the peptide's half-life from minutes to potentially hours and improve blood-brain barrier penetration. The increased potency means effective doses are in the 25-50 mcg range rather than the 200-900 mcg range required for standard Semax making accurate dosing more challenging but also making the compound more economical per effective dose.

Dosage Information

Typical Dose

25-100 mcg per dose

Frequency

Once daily

Administration

Intranasal spray

Notes

Significantly more potent than standard Semax — start at the lowest dose. Due to increased potency effects may be felt for 8-12 hours. Avoid late afternoon dosing to prevent sleep disruption.

Where does N-Acetyl Semax Amidate sit?

See how this peptide compares across all 111 peptides in our database.

Evidence Score

0.11

Clinical trials
0.0035%
Literature
0.0030%
Community
0.0020%
Completeness
0.7515%

Compound Data

N-Acetyl Semax Amidate structure

Molecular Formula

C39H54N10O10S

Molecular Weight

855.00 g/mol

IUPAC Name

(4S)-4-[[(2S)-2-acetamido-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[(2S)-2-[[2-[(2S)-2-carbamoylpyrrolidin-1-yl]-2-oxoethyl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid

PubChem CID

172638603

Potential Side Effects

Nasal irritation (common)Anxiety or overstimulation at higher doses (uncommon)Insomnia if dosed late in day (uncommon)Headache (rare)

Community Experiences

Share Your Experience

Sign in to track your experience history and vote on others.
Verifying...

No experiences shared yet. Be the first!

Quick Facts

Administration
Intranasal spray
Typical Dose
25-100 mcg per dose
Frequency
Once daily
References
0 curated + 0 from PubMed
Evidence Score
0.1 / 100